Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31518690 | 0.72 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2MAPTMAPK1TDP1 | |
| SCHEMBL3554775 | 0.72 | PPARA (0.39) | HCAR2 | |
| SCHEMBL2179646 | 0.69 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2MAPTMAPK1TDP1 | |
| SCHEMBL9088701 | 0.67 | KDM4E (0.40) | ALDH1A1SMN1; SMN2MAPTMAPK1TDP1 | |
| SCHEMBL12405041 | 0.66 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2MAPTMAPK1TDP1 | |
| SCHEMBL28106711 | 0.66 | KDM4E (0.43) | ALDH1A1SMN1; SMN2MAPTKDM4EHPGD | |
| SCHEMBL3197749 | 0.65 | PIM1 (0.48) | S100A4MAPTPIM1CDC25BKDM4E | |
| SCHEMBL11655924 | 0.64 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2KDM4EGAAHPGD | |
| SCHEMBL20657581 | 0.63 | PIN1 (0.44) | ALDH1A1SMN1; SMN2MAPTKDM4EGAA | |
| SCHEMBL22889987 | 0.63 | RXFP1 (0.40) | ALDH1A1SMN1; SMN2MAPTMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807668-B2 | Anti-inflammatory compounds | NEW ZEALAND INSTITUTE FOR CROP & FOOD RESEARCH LIMITED (NZ) | 2010-10-05 | — | — | US | disclosed |
| US-20070265253-A1 | Anti-Inflammatory Compounds | NEW ZEALAND INSTITUTE FOR CROP & FOOD RESEARCH LIMITED (NZ) | 2007-11-15 | — | — | US | disclosed |
| EP-1789422-A1 | ANTI-INFLAMMATORY COMPOUNDS | NEW ZEALAND INSTITUTE FOR CROP & FOOD RESEARCH LIMITED (NZ) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006031134-A1 | ANTI-INFLAMMATORY COMPOUNDS | NEW ZEALAND INSTITUTE FOR CROP & FOOD RESEARCH LIMITED (NZ) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265253-A1 | Anti-Inflammatory Compounds | TNF, PTGS1, PTGES | S100A4 64/4885ALDH1A1 489/4885SMN1; SMN2 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.